Alzheimer's drug Leqembi forecast to generate $12.9 billion in sales by 2028

6 April 2023
alzheimer-s-neurology-brain-dementia-big

Having received accelerated approval from US Food and Drug Administration (FDA) in January this year for their Alzheimer’s disease drug Leqembi (lecanemab), Japan’s Eisai (TYO: 4523) and US biotech Biogen (Nasdaq: BIIB) are now awaiting authorizations in the important markets of the European Union and Japan to solidify the drug’s position as the top-selling drug for Alzheimer's in the upcoming years.

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9 billion between 2023 and 2028, according to data and analytics company GlobalData.

The FDA decision on Leqembi was based on data from a Phase II clinical trial named Athena AD. The results of the trial showed that treatment led to a significant reduction in the amount of amyloid beta plaques in the brain and demonstrated a statistically significant reduction in cognitive decline in patients treated with Leqembi compared to those who received a placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology